Presenting at AHS 2022, researchers assessed the efficacy of galcanezumab 120 mg/month in the prevention of episodic migraine.
Presenting at AHS 2022, researchers evaluated the real-world effectiveness of ubrogepant in combination with onabotulinumtoxinA to treat breakthrough migraine.
Presenting at AHS 2022, researchers determined the effect of generalized anxiety disorder on the responsiveness of BoNT-A treatment from pediatric patients with chronic migraine.
Researchers sought to evaluate quality of life, disability, and functioning based on the use of preventative treatment and failure in patients with low-frequency and moderate- to high-frequency episodic migraine.
Researchers sought to assess the epidemiology of comorbid sleep disorders in patients with migraine.
Presenting at AHS 2022, researchers assessed the effect of a high-fat meal on the pharmacokinetics of immediate release atogepant tablets.
Presenting at CMSC 2022, researchers assessed the safety and efficacy of DMF for RRMS using real-world data.
Presenting at CMSC 2022, researchers obtained real-world data on the efficacy and safety of oral cladribine in patients with relapsing-remitting multiple sclerosis.
In a quantitative study, researchers assessed the efficacy of TMS on depressive symptoms in people with MS.
Presenting at CMSC 2022, researchers analyzed the development of whole-brain atrophy and white matter lesions in patients with CDMS.
